(Reuters) – Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs.
The company said it will also discontinue its Hepatitis B and HIV early programs.
Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision.
The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.